Louied91
2 months ago
SPARKS, Nev., March 06, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc. (OTC: LUDG): A US-based biotechnology company is pleased to announce the successful filing of its provisional patent, title “mRNAs differentially expressed in colorectal cancer, breast cancer, and bladder cancer.” By utilizing machine learning artificial intelligence (AI), this breakthrough is able identify specific mRNA genes associated with breast, colorectal, and bladder cancer.
These genetic findings marks a significant milestone for the company, and positions it to enter, this year, into the billion dollar diagnostic cancer screening market. The Company’s mRNA for Life™ is a one-of-the-kind noninvasive at-home sceening test for genes that could be associated with cancer. This test allows a person to make themselves a priority and could be a signal to seek a medical examination.
Ludwig, over the past 3 years, has received over 2,500 nonivasive cheek cell samples from numerous clinics in the United States as part of an IRB approved clinical study of patients with various diseases. The Company selected for measurement 48 distinct mRNA genes in stored specimens from patients afflicted with breast, bladder or colorectal cancer. mRNA levels were analyzed using machine learning artificial intelligence (AI) to identify markers of genetic expression involved in separate cancers. The filed patent application describes a method to use buccal or cheek cells as a surrogate tissue from which to isolate sufficient nanogram amounts of mRNA that can be measured in proprietary custom designed microarray chips produced by Thermo Fisher Scientific for Ludwig. Buccal cells are ideal surrogate tissues for studying levels of mRNA.
Epigenetic regulation through mRNA is an important mode of cellular control in the development of cancer. Cancer development is a complex phenomenon that involves growth factors, cytokines and extracellular enzymes that shape the environment in the tissue as well as around the cancer. It is important to define the elements of mRNA transcripts that shape and sculpt the epigenome within each cell type during each cellular reprogramming event as well as how the changing epigenomes within the tumor and stroma can act in synergy during tumor progression.
Epigenetics is the study of how a person’s behaviors and environment can cause changes that affect the way your genes work. Unlike genetic changes, epigenetic changes are reversible and do not change your DNA sequence, but they can change how your body reads a DNA sequence.
Marvin S. Hausman MD, CEO, stated: “We may have discovered a potential holy grail in medicine that uses mRNA genetic information to allow early and more accurate prediction and diagnosis of disease and disease progression. Using this unique screening via mRNA biomarkers we have uncovered cancer genetic predisposition, and enable the establishment, on a personalized basis, treatment and response to therapy.”
dounome
12 months ago
ACCESSWIRE
Ludwig Enterprises to Launch New Nutraceutical in Hair Loss Market
Ludwig Enterprises Inc.
Wed, May 3, 2023 at 7:00 AM EDT
In this article:
LUDG
0.00%
Watchlist
Watchlist
SPARKS, NV / ACCESSWIRE / May 3, 2023 / Ludwig Enterprises, Inc, (OTC PINK:LUDG) (Ludwig - The Genomics Language Company™) is planning to expand its direct to consumer and direct to professional sales and marketing strategies to include individuals facing hair loss associated with inflammation.
Clinical researchers are studying the impact that inflammation, and the genomic biomarkers that regulate this process, could have on hair loss. mRNA biomarkers, TNF-a and CASP7, are overexpressed in moderate male and female pattern hair loss. Researchers have also emphasized the possible benefits associated with Niacin, Folic Acid, Vitamin E, and several B Vitamins as it relates to hair loss and healthy hair.
NuGenea™ is Ludwig Enterprise's ground-breaking nutraceutical that has been scientifically formulated to directly impact the mRNA biomarkers of inflammation including CASP7 and TNF-a. NuGenea's 20 ingredients also include those associated with healthy hair and the potential to support normal hair growth.
"I personally researched published scientific studies revealing the value of the 20 ingredients that are included in NuGenea's formula," said Dr. Marvin S. Hausman MD, its creator. "I found 84 scientific studies that demonstrated how these compounds have the potential to impact mRNA biomarkers of chronic inflammation, also called cytokines and chemokines, including those associated with male and female pattern hair loss."
"Approximately 80 million people in the US are suffering from hair loss," said Luke Fannon Ludwig's Chief Marketing Officer. "Hair loss significantly impacts self-esteem, and we believe that we can have a significant impact on lives of people who suffer from male and female pattern hair loss."
"Ludwig Enterprises plans on expanding our sales and marketing strategy to educate consumers about NuGenea's potential impact for hair loss sufferers," added Fannon. "We will also be working directly with trichologists and other salon professionals on bringing NuGenea to their clients."
NuGenea will be available direct to consumers via Ludwig's new website which will be launched shortly. For advanced orders consumers can send an email toNuGenea@ludg.us and request to be the first to receive this product. Healthcare professionals who want to discuss wholesale purchases of the product can call NuGenea's product launch department at 484-429-5846.
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. is a healthcare holding company focused on cutting edge mRNA genomic technology, therapeutics, and nutraceuticals. Through its subsidiary Precision Genomics, it has a patent pending on the mRNA Inflammatory Index™ that measures 48 different biomarkers of inflammation. Combined with AI and deep machine learning this technology may enable healthcare professionals to identify sources of chronic inflammation and potentially prevent chronic illnesses such as diabetes, COPD, heart disease and cancer. NuGenea™, a scientifically formulated nutraceutical, supported by decades of independent research into the anti-inflammatory properties of its compounds, is manufactured by the Ludwig subsidiary mRNAforLife, Inc.
Advancements in medical technology have awarded us with cutting-edge genomic tools, unheard of even a generation ago. These genomic tools have the potential to not only detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era of medicine with their proprietary mRNA genomic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including, but not limited to heart disease, diabetes, preeclampsia, and cancer. This early detection may allow doctors to take steps to diagnose and manage illness before it progresses and causes serious health problems. Ludwig's innovative testing approach is not only practical but also has the potential to save the healthcare industry millions of dollars in costs. With a virtually untapped market and a billion-dollar healthcare industry, Ludwig and its subsidiaries Precision Genomics, Inc and mRNAforLife, Inc. are poised to significantly impact how we think about disease and live longer healthier lives. For more information please visit: http://www.ludwigent.com.
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
dounome
1 year ago
Ludwig Enterprises Announces Launch of New Nutraceutical and Strategic Marketing Plan
LUDG
0.00%
Ludwig Enterprises Inc.
Tue, April 25, 2023 at 9:00 AM EDT
In this article:
LUDG
0.00%
Watchlist
Watchlist
SPARKS, NV / ACCESSWIRE / April 25, 2023 / Ludwig Enterprises, Inc., OTC:LUDG (Ludwig - The Genomics Language Company) has released its strategic sales and marketing plan as it launches its ground-breaking nutraceutical, NuGenea™. NuGenea, which means ‘New Life" in Greek, is a nutraceutical created by a physician and formulated with 20 different ingredients which have been scientifically shown to help fight chronic inflammation.
"Chronic inflammation is a causative factor in illnesses such as cancer, diabetes, COPD and heart disease," said Dr. Marvin S. Hausman MD, NuGenea's creator. "The World Health Organization estimates that more than 50% of the world's deaths result from these illnesses. We believe NuGenea has the potential to improve the health of a large number of people."
"Ludwig's primary sales and marketing strategies for NuGenea will include Direct to Consumer and Direct to Healthcare Professionals," said Luke Fannon, Chief Marketing Officer. "The company's new ecommerce website will debut shortly, and consumers will be able to purchase the product directly. We are very excited to offer discounts for volume purchases and monthly product memberships."
NuGenea's direct to consumer strategy will include digital and traditional advertising, content and native marketing and placement in retail locations.
Integrative Medicine Professionals, which includes physicians, chiropractors, naturopathic physicians, and wellness clinics, will be a major focus for Ludwig's sales and marketing team according to Fannon. "This fast-growing branch of professionals believes in a holistic approach to their patient's care which includes lifestyle and diet changes, improvements in diets and usage of nutraceuticals," added Mr. Fannon.
Consumers interested in placing an advanced order for NuGenea can send an email toNuGenea@ludg.us and request to be the first to receive this product. Healthcare professionals who want to discuss wholesale purchases of the product can call NuGenea's product launch department at 484-429-5846.
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. is a healthcare holding company focused on cutting edge mRNA genomic technology, therapeutics, and nutraceuticals. Through its subsidiary Precision Genomics, it has a patent pending on the mRNA Inflammatory Index™ that measures 48 different biomarkers of inflammation. Combined with AI and machine learning this technology may enable healthcare professionals to identify sources of chronic inflammation and potentially prevent illnesses such as diabetes, COPD, heart disease and cancer. NuGenea™, a scientifically formulated nutraceutical, supported by decades of independent research into the anti-inflammatory properties of its compounds, is manufactured by the Ludwig subsidiary mRNAforLife, Inc and its My RNA for Life™ product line of nutraceuticals.
Advancements in medical technology have awarded us with cutting-edge genomic tools, unheard of even a generation ago. These genomic tools have the potential to not only detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era of medicine with their proprietary mRNA genomic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including, but not limited to heart disease, diabetes, preeclampsia, and cancer. This early detection may allow doctors to take steps to diagnose and manage illness before it progresses and causes serious health problems. Ludwig's innovative testing approach is not only practical but also has the potential to save the healthcare industry millions of dollars in costs. With a virtually untapped market and a billion-dollar healthcare industry, Ludwig and its subsidiaries Precision Genomics, Inc and mRNAforLife, Inc. are poised to significantly impact how we think about disease and live longer healthier lives. For more information please visit: http://www.ludwigent.com.
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
dounome
1 year ago
SPARKS, NV / ACCESSWIRE / March 7, 2023 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), The Genomics Language Company™ is pleased to announce an agreement with Drs. Kim Farahay and Jeff Lee to provide them with the Company's newly developed program for use of the mRNA Inflammatory Index™ in Ketamine treatment of patients with Treatment Resistant Depression. Drs. Farahay and Lee are finalizing plans to open a Ketamine clinic in southeastern Ohio in 2023.
"Major depressive disorder is one of the leading causes of morbidity and all-cause mortality (including suicide) worldwide," said Dr. Marvin S. Hausman, MD, Chief Medical Officer of Ludwig Enterprises, and creator of the mRNA Inflammatory Index™. "Our mRNA Inflammatory Index could become a reliable and reproducible biomarker guide to patient treatment selection, evaluation of ketamine dosage used and therapeutic response."
Ketamine is a pharmaceutical discovered over 60 years ago originally approved by the FDA as an anesthetic and analgesic. It was first used psychotherapeutically and for post operative pain in 1974. It was added to the WHO's list of Essential Medicines in 1985. Studies in the early 2000s found Ketamine to be effective in fighting depression resistant to other treatments.
"The ketamine clinic industry is growing rapidly," said Dr. Jeff Lee, the clinic's co-founder. "Our partnership with Ludwig - The Genomics Language Company™ will provide artificial intelligence (AI) to track mRNA inflammatory markers in patients with treatment resistant depression who are undergoing Ketamine therapy, which would be a huge breakthrough for the industry. This statistical analytical approach will assist in substantiating the patient's subjective reporting experience and may allow adjustment of treatment dosage."
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. is a healthcare holding company focused on cutting edge mRNA genomic technology, therapeutics and nutraceuticals. Through its subsidiary Precision Genomics it has a patent pending on the mRNA Inflammatory Index™ that measures 48 different biomarkers of inflammation. Combined with AI and deep machine learning this technology may enable healthcare professionals to identify sources of chronic inflammation and potentially prevent chronic illnesses such as diabetes, COPD, heart disease and cancer. NuGenea™, a scientifically formulated nutraceutical, supported by decades of independent research into the anti-inflammatory properties of its compounds, is manufactured by the Ludwig subsidiary mRNAforLife, Inc and it's My RNA for Life™ product line of nutraceuticals.
Advancements in medical technology have awarded us with cutting-edge genomic tools, unheard of even a generation ago. These genomic tools have the potential to not only detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era of medicine with their proprietary mRNA genomic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including, but not limited to heart disease, diabetes, preeclampsia and cancer. This early detection may allow doctors to take steps to diagnose and manage illness before it progresses and causes serious health problems. Ludwig's innovative testing approach is not only practical but also has the potential to save the healthcare industry millions of dollars in costs. With a virtually untapped market and a billion-dollar healthcare industry, Ludwig and its subsidiary Precision Genomics is poised to significantly impact how we think about disease and live longer healthier lives. For more information please visit: http://www.ludwigent.com.
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Precision Genomics & Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Ludwig Enterprises, Inc.
Anne Blackstone, CEO
786-235-9026
www.ludwigent.com
SOURCE: Ludwig Enterprises, Inc.
View source version on accesswire.com:
https://www.accesswire.com/742439/Ludwig-Enterprises-Develops-Program-to-Support-Ketamine-Clinics
Level up your trading with our powerful tools and real-time insights all in one place.
Monroe1
3 months ago
QuicKtip
1 year ago
Hot Features
Premium
